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OBJECTIVE
To assess the diagnostic utility of corneal confocal microscopy (CCM) for diabetic
peripheral neuropathy (DPN) and the risk factors for corneal nerve loss.
RESEARCH DESIGN AND METHODS
A total of 490 participants, including 72 healthy control subjects, 149 with type 1
diabetes, and 269with type 2diabetes, underwent detailed assessment of peripheral
neuropathy and CCM in relation to risk factors.
RESULTS
Corneal nerve fiber density (CNFD) (P < 0.0001 and P < 0.0001), corneal nerve fiber
branch density (CNBD) (P < 0.0001 and P < 0.0001), and corneal nerve fiber length
(CNFL) (P< 0.0001 and P5 0.02)were significantly lower in patientswith type 1 and
type 2 diabetes compared with control subjects. CNFD (P < 0.0001), CNBD (P <
0.0001), and CNFL (P < 0.0001) were lower in type 1 diabetes compared with type 2
diabetes. Receiver operating characteristic curve analysis for the diagnosis of DPN
demonstrated a goodareaunder the curve for CNFDof 0.81, CNBDof 0.74, andCNFL
of 0.73. Multivariable regression analysis showed a significant association among
reduced CNFL with age (b 5 20.27, P 5 0.007), HbA1c (b 5 21.1; P5 0.01), and
weight (b520.14; P5 0.03) in patients with type 2 diabetes and with duration of
diabetes (b520.13;P50.02), LDL cholesterol (b51.8,P50.04), and triglycerides
(b 5 22.87; P 5 0.009) in patients with type 1 diabetes.
CONCLUSIONS
CCM identifies more severe corneal nerve loss in patients with type 1 diabetes
compared with type 2 diabetes and shows good diagnostic accuracy for DPN.
Furthermore, the risk factors for a reduction in corneal nerve fiber length differ
between type 1 and type 2 diabetes.
Diabetic peripheral neuropathy (DPN) is themost frequent long-term complication of
diabetes (1). The diagnosis of DPN relies on abnormal symptoms and signs and
electrophysiology. However, these tests do not reliably detect early damage to the
small nerve fibers. Quantifying intraepidermal nerve fiber density is the gold standard
for the assessment of small fiber damage but is an invasive procedure (2,3). Corneal
confocal microscopy (CCM) is a rapid, noninvasive, ophthalmic imaging tool that is
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comparable to skin punch biopsy in the
diagnosis of DPN (4) and allows objective
assessment of early corneal nerve de-
generation (5) and regeneration after an
improvement in risk factors (6) and si-
multaneous pancreas and kidney trans-
plantation (7). Corneal nerve fiber length
(CNFL) is a valid predictor for incident
DPN in patients with type 1 diabetes (8),
and corneal nerve fiber density (CNFD)has
the highest diagnostic performance to
identify DPN in patients with type 1
and type 2 diabetes (4,9).
Several mechanisms may be involved
in the development of DPN, including
hyperglycemia-driven abnormalities of
the polyol pathway, advanced glycation
end products, and dyslipidemia (10).
Furthermore, high BMI, hypertension,
cholesterol, and triglycerides levels are
associated with incident DPN in type 1
diabetes (11), and age, BMI, waist cir-
cumference, LDL cholesterol, and HDL
cholesterol are associated with incident
DPN in type 2 diabetes (12).
Small cohort studies have reported
an association between clinical and met-
abolic variables and CCM measures
(6,13–16), particularly with HbA1c (17),
duration of diabetes (18), and HDL cho-
lesterol (16) in both type 1 and type 2
diabetes (19) and with age, duration of
diabetes (14,15), blood pressure, and
HbA1c (20) in type 1 diabetes. However,
in patients with type 2 diabetes, there
was no association between corneal
nerve loss and HbA1c (21), but there
was an association with total and LDL
cholesterol (13). Subjects with impaired
glucose tolerance also develop corneal
nerve loss (22), indicating the role of
additional risk factors beyond elevated
blood glucose. Corneal nerve loss has
been associated with higher triglycerides
in patients with idiopathic small fiber
neuropathy (23).
We have undertaken CCM to assess its
diagnostic utility, the relationship with
other measures of neuropathy, and the
risk factors for corneal nerve fiber loss in
patients with type 1 and type 2 diabetes.
RESEARCH DESIGN AND METHODS
Study Subjects
This study assessed 490 participants, includ-
ing 72 healthy control subjects, 149 with
type1diabetes, and269withtype2diabetes,
who took part in the Longitudinal Assess-
ment of Neuropathy in DiabetesUsingNovel
OphthalmicMarkers (LANDMark) (16), Prob-
ing the Role of Sodium Channels in Painful
Neuropathies (PROPANE) (24), andDEAMON
(25) studies between 2007 and 2017. All
participants underwent detailed assessment
of neuropathy and CCM. Patients with a
historyofneuropathy (other thandiabetes),
current or active diabetic foot ulceration,
chronic renal and liver failure, malignancy,
systemic disease, deficiency of B12 or folate,
previous corneal trauma, corneal disease,
corneal surgery, and a history of or current
contact lens wear were excluded from the
study. The research adhered to the tenets of
theDeclarationofHelsinkiandwasapproved
by the Greater Manchester Research Ethics
Committees(Manchester,U.K.).Writtencon-
sent forms were obtained from all partic-
ipants prior to their participation.
Clinical and Peripheral Neuropathy
Assessment
All participants underwent an assess-
ment of BMI, blood pressure, HbA1c,
and lipid profile. The neuropathy symp-
tom profile (NSP) was administered to
assess symptoms of DPN, and the mod-
ified neuropathy disability score (NDS)
was used to assess pinprick, vibration
perception, temperature sensation, and
ankle reflexes. The ANX 3.0 autonomic
nervous system monitoring device (AN-
SAR Medical Technologies, Inc., Media,
PA) was used to measure the heart rate
response to deep breathing over two
eight-cycle breathing series separated
by a 5-min period of normal breathing
and was reported as deep-breathing
heart rate variability (DB-HRV) (9).
Vibration perception threshold (VPT)
was evaluated using a Horwell Neuro-
thesiometer (Scientific Laboratory Sup-
plies Ltd., Nottingham, U.K.). The probe
of the device was placed on the tip of the
big toe, and the individual was asked to
report if the vibration was felt as the
intensity was gradually increased from
0to50V.Coldperception threshold (CPT),
warm perception threshold (WPT), and
cold- and warm-induced pain (CIP and
WIP) were assessed using a TSA 2 Neuro-
Sensory Analyzer (Medoc, Ltd., Ramat
Yishay, Israel) on the dorsum of the non-
dominant foot in the S1 dermatome. The
temperature was changed using a stair-
case algorithm, and the individual was
askedwhetherthewarmorcoldsensation
and WIP or CIP were felt. Nerve conduc-
tion studies were undertaken using
the Dantec Keypoint system (Dantec
Dynamics Ltd., Bristol, U.K.), anda therm-
istor (temperature regulator; DISA Indus-
tries, Taastrup, Denmark) maintained the
limb temperature between 32 and 35°C. A
consultant neurophysiologist assessed su-
ral nerve amplitude (SNAP), sural nerve
conduction velocity (SNCV), peroneal mo-
tornerveamplitude(PMNA),andperoneal
motor nerve conduction velocity (PMNCV).
DPN was defined according to the
Toronto consensus (3), which requires
the presence of symptoms (abnormal
NSP) or signs of neuropathy (NDS .2)
and abnormal peroneal nerve conduc-
tion velocity (PMNCV ,40 m/s).
Skin Biopsy
Three-millimeter skin punch biopsies were
taken from the dorsum of the foot, 2 cm
above the second metatarsal head under
local anesthetic (1% lidocaine) in control
subjects (n5 15) and patients with type 1
(n5 67) and type 2 diabetes (n5 50). The
biopsy was fixed in 4% paraformaldehyde,
cryoprotected in graded solutions of su-
crose, frozen, and cut on a cryomicrotome
(HM 450; Microm International GmbH,
Walldorf, Germany). The 50-mm sections
wereimmunostainedusinganti-humanPGB
9.5 antibody (Abcam, Cambridge, U.K.), and
nerve fibers were demonstrated using SG
chromogen (Vector Laboratories, Peterbor-
ough, U.K.). Intraepidermal nerve fiber den-
sity (IENFD) was expressed as the number
of nerve fibers per millimeter and quanti-
fied according to established criteria (4).
CCM
CCM was performed in both eyes using
laser scanning CCM (Heidelberg Retina
Tomograph 3 Rostock Cornea Module;
Heidelberg Engineering, Heidelberg, Ger-
many) to acquire images of the cornea
(9), and six images (three per eyes) were
selected according to the quality, posi-
tion, and depth of the central subbasal
nerve plexus (26). Manual analysis was
undertaken using CCMetrics (The Uni-
versity of Manchester) in a masked and
randomized fashion. CNFD (total number
of main nerves per square millimeter),
corneal nerve fiber branch density
(CNBD; total number of branches per
square millimeter), and CNFL (total
length of main nerves and nerve
branches per square millimeter) were
quantified.
Statistical Analysis
The analysis was carried out using SPSS
(Version 22.0 for windows; IBM Corpo-
ration, New York, NY). Data were tested
for normality using the Shapiro-Wilk test,
visualization of histograms, and Q-Q plots
and presented as mean 6 SEM. ANOVA
with Bonferroni correction was used to
compare means among groups. We per-
formed an ANCOVA with least significant
difference correction to control for age
as a confounder in our neuropathy as-
sessment comparisons among groups.
Generalized linear models were used to
explore the association between CCM
measures and clinical findings. The Pear-
son correlation coefficient (parametric)
or Spearman rank correlation coefficient
(nonparametric) was used to determine
the correlation between variables.
Receiver operating characteristic (ROC)
curve analysis was performed for corneal
nerve parameters. The area under the
curve (AUC) for each parameter to di-
agnose DPN was determined by selecting
the cutoff point for a concurrently opti-
mized sensitivity and specificity at a ratio
of 1:1. As the age of the control partic-
ipants and patientswith type 1 and type 2
diabetes differed, we also compared 199
patients with type 2 diabetes with 43 age-




Age differed significantly between con-
trol subjects and patientswith type 1 and
type2diabetes (47.0461.61 vs. 48.816
1.37 and 62.59 6 0.59; P , 0.0001).
There was a significant difference in BMI
(P , 0.0001), waist circumference (P ,
0.0001), HbA1c (P 5 0.002), estimated
glomerular filtration ratio (P , 0.0001),
total cholesterol (P , 0.0001), HDL cho-
lesterol (P , 0.0001), triglycerides (P ,
0.0001), and LDL cholesterol (P, 0.0001),
but no difference in smoking (P5 0.2) or
alcohol consumption (P 5 0.7) between
groups (Table 1).
Peripheral Neuropathy Assessment
NDS was significantly higher in type 1
(4.29 6 0.22; P , 0.0001) and type 2
diabetes (3.13 6 0.17; P , 0.0001)
compared with control subjects (1.37 6
0.32) and was significantly higher in
type 1 compared with type 2 diabetes
(P,0.0001).NSPwas significantlyhigher
in type 1 (5.3 6 0.4; P , 0.0001) and
type 2 diabetes (4.9 6 0.5; P , 0.0001)
compared with control subjects (0.8 6
0.6) but did not differ between type 1 and
type 2 diabetes (P 5 0.8). DB-HRV was
significantly lower in patients with type 1
(21.75 6 1.03; P 5 0.03) and type 2
diabetes (20.56 6 1.05; P 5 0.01) com-
pared with healthy control subjects
(25.9660.75) but did not differ between
patients with type 1 and type 2 diabetes
(P5 0.4). VPT was significantly higher in
type 1 (18.98 6 0.8 V; P , 0.0001) and
type 2 diabetes (13.776 0.61 V; P5 0.001)
compared with control subjects (9.85 6
1.14 V) and was higher in type 1 compared
with type2diabetes (P,0.0001).WPTwas
significantly higher in type 1 (41.23 6
0.34°C; P , 0.0001) and type 2 diabetes
(40.57 6 0.25°C; P , 0.0001) compared
with control subjects (38.0060.47°C),with
no difference between type 1 and type 2
diabetes. WIP was significantly higher in
type 1 (46.82 6 0.25°C; P , 0.0001) and
type2diabetes (47.660.22°C;P,0.0001)
compared with control subjects (45.22 6
0.3°C) and was lower in type 1 compared
with type 2 diabetes (P 5 0.03). CIP was
significantly lower in type 1 (7.066 0.75°C;
P 5 0.001) and type 2 diabetes (5.9 6
0.66°C; P, 0.0001) comparedwith control
subjects (10.69 6 0.89°C), with no differ-
ence between type 1 and type 2 diabetes
(P 5 0.2). CPT was significantly lower in
type1 (23.4760.46°C;P,0.0001) but not
intype2diabetes(26.0560.34°C;P50.06)
compared with control subjects (27.45 6
0.6°C) and was significantly lower in type 1
compared with type 2 diabetes (P ,
0.0001). IENFD was significantly lower in
type 1 diabetes (5.46 6 0.56/mm; P 5
0.002) but not in type 2 diabetes (6.85 6
0.7/mm; P 5 0.1) compared with control
subjects (8.66 0.85/mm) and did not differ
between type 1 and type 2 diabetes (P 5
0.1). SNCV was lower in type 1 (39.26 6
0.54 m/s; P, 0.0001) and type 2 diabetes
(45.606 0.41 m/s; P, 0.0001) compared
withcontrol subjects (48.8260.77m/s)and
was significantly lower in type 1 compared
with type2diabetes (P,0.0001).SNAPwas
lower in type1(6.3560.57mV;P,0.0001)
and type 2 diabetes (10.866 0.43mV; P,
0.0001) compared with control subjects
(17.16 6 0.81 mV) and was significantly
lower in type 1 compared with type 2 di-
abetes (P , 0.0001). PMNCV was signifi-
cantly lower intype1(38.2260.55m/s;P,
0.0001) and type 2 diabetes (44.07 6
0.41m/s;P50.002) comparedwith control
subjects (46.89 6 0.78 m/s) and was
significantly lower in type 1 compared
with type 2 diabetes (P , 0.0001).
PMNA was significantly lower in type 1
diabetes (2.76 6 0.19 mV; P , 0.0001)
but not in type 2 diabetes (3.86 6
0.14 mV; P 5 0.06) compared with
control subjects (4.44 6 0.27 mV)
and was significantly lower in type 1
compared with type 2 diabetes (P ,
0.0001) (Table 2).
CCM
CNFD (22.37 6 0.67 vs. 34.06 6 0.95/
mm2; P , 0.0001), CNBD (47.13 6 3.11
vs. 83.396 4.39/mm2; P, 0.0001), and
CNFL (17.8460.59 vs. 24.7660.84mm/
mm2; P , 0.0001) were significantly
lower in type 1 diabetes compared
with control subjects. CNFD (25.98 6
0.51 vs. 34.066 0.95/mm2; P, 0.0001),
CNBD (63.22 6 2.36 vs. 83.39 6 4.39/
mm2; P , 0.0001), and CNFL (22.46 6
0.45 vs. 24.76 6 0.84 mm/mm2; P 5
0.02) were significantly lower in type 2
diabetes compared with healthy control
subjects. CNFD (P, 0.0001), CNBD (P,
0.0001), and CNFL (P , 0.0001) were
significantly lower in type 1 compared
with type 2 diabetes (Fig. 1 and Table 2).
Association Between CNFD and Other
Measures of Neuropathy
In patients with type 2 diabetes, CNFD
correlatedwithNDS (r520.1;P50.04),
CPT (r5 0.2; P5 0.007), VPT (r520.2;
P 5 0.002), SNCV (r 5 0.1; P 5 0.03),
SNAP (r 5 0.2; P 5 0.002), and PMNCV
(r 5 0.1; P 5 0.003), but not IENFD
(r 5 20.02; P 5 0.8), DB-HRV (r 5
0.06; P 5 0.4), WPT (r 5 20.07; P 5
0.2), WIP (r 5 20.1; P 5 0.2), CIP (r 5
0.05;P50.5),andPMNA(r50.1;P50.06).
In patients with type 1 diabetes, CNFD
correlated with NDS (r 5 20.5; P ,
0.0001), DB-HRV (r 5 0.5; P ,
0.0001), WPT (r 5 20.4; P , 0.0001),
CPT (r5 0.4; P, 0.0001),WIP (r520.4;
P , 0.0001), CIP (r 5 0.4; P , 0.0001),
VPT (r 5 20.6; P , 0.0001), SNCV (r 5
0.5; P , 0.0001), SNAP (r 5 0.5; P ,
0.0001), PMNCV (r 5 0.5; P , 0.0001),
PMNA (r 5 0.5; P , 0.0001), and IENFD
(r 5 0.2; P 5 0.05).
Diagnostic Utility of CCM
Based on the Toronto criteria, 27.7% of
patients were diagnosed with DPN. The
ROC curve analysis for CCM in the di-
agnosis of DPN showed that CNFD had
the highest AUC at 0.81 with an optimal
cutoff point of 29.40/mm2, sensitivity of
73.5%, and specificity of 74.4%. CNBD
hadanAUCof 0.74with anoptimal cutoff
point of 64.58/mm2, sensitivity of 66.7%,
and specificity of 66.7%. CNFL had the
lowest AUC of 0.73, with an optimal
cutoff point of 24.00 mm/mm2, sensitiv-
ity of 66.7%, and specificity of 66.4%
(Supplementary Table 2 and Fig. 2).
Multivariable Regression Analysis
In patients with type 1 diabetes, the
reduction in CNFL was associated with
higher triglycerides (b 5 22.87; P 5
0.009), LDL cholesterol (b 5 1.8; P 5
0.04), anddurationof diabetes (b520.13;
P5 0.02). In patients with type 2 diabetes,
reduced CNFL was associated with higher
age (b 5 20.27; P 5 0.007), HbA1c
(b 5 21.1; P 5 0.01), and weight
(b 5 20.14; P 5 0.03) (Supplementary
Table 3).
CONCLUSIONS
CCM has shown a reduction in corneal
nerve fibers in small cohorts of patients
with DPN (8,27). However, there is an
inconsistency in the literature in relation
to differences between patients with
type 1 and type 2 diabetes and the
risk factors associatedwith corneal nerve
loss and DPN (6,14,16,20). In this large
study of predominantly Europeans, we
show greater corneal nerve loss in pa-
tients with type 1 compared with type 2
diabetes. We also demonstrate differ-
ences in the risk factors associated with
corneal nerve loss in patients with type 1
and type 2 diabetes. This is consistent
with data indicating that the natural
history and risk factors for DPN may
differ between type 1 and type 2 diabetes
(28) and that components of the meta-
bolic syndrome may contribute to DPN
(29). Ethnicity may also contribute to
Table 1—Clinical, demographic, and laboratory results in control subjects and patients with type 1 and type 2 diabetes
Control subjects (n 5 72) Type 2 diabetes (n 5 269) Type 1 diabetes (n 5 149) ANOVA P value
Age (years) 47.04 6 1.61 62.59 6 0.59* 48.81 6 1.37$ ,0.0001
Ethnicity (European) (%) 63.9 63.2 94.00 ,0.0001
Sex (female) (%) 54.2 33.8 46.30 0.005
Duration of diabetes (years) NA 11.03 6 0.47 30.21 6 1.44$ ,0.0001
BMI (kg/m2) 26.65 6 0.58 32.08 6 0.42* 27.04 6 0.41$ ,0.0001
Waist circumference (cm) 89.57 6 1.72 107.55 6 1.09* 91.07 6 1.46$ ,0.0001
Smoking (number/day) 0.42 6 0.21 0.84 6 0.33 1.38 6 0.38 0.2
Alcohol (units/week) 4.27 6 0.84 5.24 6 0.71 4.97 6 0.63 0.7
HbA1c, % (mmol/mol) 5.6 6 0.05 (37.76 6 0.42) 7.8 6 0.09 (62.03 6 3.9)* 8.1 6 0.12 (65.28 6 1.34)* 0.002
eGFR (mL/min/1.73 m2) 84.64 6 1.05 72.81 6 1.53* 77.22 6 1.69* ,0.0001
Total cholesterol (mmol/L) 5.12 6 0.11 4.04 6 0.06* 4.33 6 0.07*$ ,0.0001
HDL cholesterol (mmol/L) 1.55 6 0.05 1.23 6 0.03* 1.68 6 0.04$ ,0.0001
Triglycerides (mmol/L) 1.48 6 0.09 1.96 6 0.07* 1.18 6 0.07$ ,0.0001
LDL cholesterol (mmol/L) 2.95 6 0.09 1.97 6 0.05* 2.13 6 0.06* ,0.0001
Data are mean 6 SEM. eGFR, estimated glomerular filtration rate; NA, not applicable. *Significant difference compared with control subjects.
$Significant difference compared with type 2 diabetes.
Table 2—CCM and other measures of neuropathy in control subjects and patients with type 1 and type 2 diabetes
Parameters Control subjects (n 5 72) Type 2 diabetes (n 5 269) Type 1 diabetes (n 5 149) ANCOVA P value
CNFD (number/mm2) 34.06 6 0.95 25.98 6 0.51* 22.37 6 0.67*$ ,0.0001
CNBD (number/mm2) 83.39 6 4.39 63.22 6 2.36* 47.13 6 3.11*$ ,0.0001
CNFL (mm/mm2) 24.76 6 0.84 22.46 6 0.45* 17.84 6 0.59*$ ,0.0001
IENFD (number/mm) 8.60 6 0.85 6.85 6 0.7 5.46 6 0.56* 0.007
NDS (0–10) 1.37 6 0.32 3.13 6 0.17* 4.29 6 0.22*$ ,0.0001
NSP (0–38) 0.8 6 0.6 4.9 6 0.5* 5.3 6 0.4* ,0.0001
DB-HRV (bpm) 25.96 6 1.75 20.56 6 1.05* 21.75 6 1.03* 0.04
VPT (V) 9.85 6 1.14 13.77 6 0.61* 18.98 6 0.8*$ ,0.0001
CPT (°C) 27.45 6 0.6 26.05 6 0.34 23.47 6 0.46*$ ,0.0001
WPT (°C) 38.00 6 0.47 40.57 6 0.25* 41.23 6 0.34* ,0.0001
CIP (°C) 10.69 6 0.89 5.9 6 0.66* 7.06 6 0.75* ,0.0001
WIP (°C) 45.22 6 0.3 47.6 6 0.22* 46.82 6 0.25*$ ,0.0001
SNCV (m/s) 48.82 6 0.77 45.60 6 0.41* 39.26 6 0.54*$ ,0.0001
SNAP (mV) 17.16 6 0.81 10.86 6 0.43* 6.35 6 0.57*$ ,0.0001
PMNCV (m/s) 46.89 6 0.78 44.07 6 0.41* 38.22 6 0.55*$ ,0.0001
PMNA (mV) 4.44 6 0.27 3.86 6 0.14 2.76 6 0.19*$ ,0.0001
Dataaremean6SEMcorrected forageusingANCOVA(least significantdifference correction). All symbols represent statistically significantdifferences.
bpm, beats per minute. *Significant difference compared with control subjects. $Significant difference compared with type 2 diabetes.
differences in DPN, as we have previously
shown that corneal nerves are more
preserved in South Asians compared
withEuropeanswith type2diabetes (25).
In type 1 diabetes, we show that cor-
neal nerve loss is associated with the
duration of diabetes, triglycerides, and
LDL cholesterol. The association between
duration of diabetes and corneal nerve
loss may be attributed to the longer
durationofdiabetesandpresenceofearly
corneal nerve fiber loss even in children
with type 1 diabetes (30). Dehghani et al.
(15) also reported that a longer duration
of diabetes was associated with reduced
CNFD and CNBD in patients with type 1
diabetes. With regard to the relationship
between lipids and corneal nerves, fibrate
and statin therapy has been associated
with a reduced incidence of DPN (31), and
increased triglycerides are associated with
incident DPN (32) and amputation (33).
The Diabetes Control and Complications
Trial (DCCT) also demonstrated that
elevated triglycerides were a risk fac-
tor for the development of DPN in pa-
tients with type 1 diabetes (34). A
univariate analysis has previously shown
that LDL was related to CNFD and total
cholesterol was related to CNFD and
CNFL in patients with type 2 diabetes
(13).
In type 2 diabetes, we show that cor-
neal nerve loss is associated with HbA1c,
age, and weight. Studies have shown an
association between HbA1c and corneal
nerve loss in type 2 diabetes (13). Fur-
thermore, several interventional studies
in patients with type 2 diabetes have
demonstrated that a reduction in HbA1c
was associated with an improvement in
corneal nerve morphology (35–37). The
association between older age and re-
duced CNFL agrees with Andersen et al.
(13), who also reported an association
between older age and reduced CNFD.
With regard to weight, a recent study
has shown that a reduction in weight in
patients with type 2 diabetes was asso-
ciated with an improvement in corneal
nerve morphology (36).
We show that CCM, a marker of small
fiber damage, has reasonable diagnostic
utility for DPN in patients with type 1 and
type2diabetesdespiteusing theToronto
criteria, which is large fiber weighted for
the diagnosis of DPN. Previously, Petro-
poulos et al. (27) demonstrated that
CNFL had the highest diagnostic utility
forDPNwith anAUCof0.75, sensitivity of
0.76, and specificity of 0.65. However,
similar to the current study, Alam et al. (9)
reported that CNFD had the highest AUC
of 0.81 with a sensitivity of 0.77 and
specificity of 0.79. In a large cohort of
patients with type 1 and type 2 diabetes,
Perkins et al. (38) reported comparable
diagnostic utility for DPN using auto-
mated CNFL with an AUC of 0.77 in
type 1 diabetes and 0.71 in type 2 di-
abetes. Given that the patients with
Figure 1—CCM images of the central cornea in a healthy control subject (A), an age-matched patient with type 2 diabetes (B), and an age-matched
patient with type 1 diabetes (C).
Figure 2—ROC curves for CNFL, CNFD, and CNBD.
type 2 diabetes were older than those
with type 1 diabetes and control subjects,
an age-adjusted ANCOVAwas performed
to compare means between groups, and
further analysis was undertaken with an
older control group. Furthermore, the
patients had relatively well-controlled
risk factors for DPN, which may impact
ontherelativestrengthoftheassociations
between risk factors and severity of cor-
neal nerve loss.
In conclusion, this study provides ro-
bust evidence from a large cohort of
patients with type 1 and type 2 diabetes
that CCM is a valid biomarker to evaluate
neurodegeneration in human diabetic
neuropathy. We also show that the se-
verity and risk factors for corneal nerve
loss and the relationship between CCM
and other measures of neuropathy differ
between patients with type 1 and type 2
diabetes. Further studies are required
to establish the relationship between
CCM and patient-oriented outcomes
such as pain, disability, and quality of
life. Longitudinal and interventional
studies are also required to determine
the natural history of corneal nerve fiber
loss and the utility of CCM in clinical trials
of DPN.
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